Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone — OPAL

Opioid-Induced Bowel Dysfunction Clinical Trial

Official title:
A Multi-center, Randomized, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction (OBD)

Status Completed

Clinical Trial Summary

The primary purpose of this study is to evaluate the efficacy and safety of lubiprostone administration in patients with opioid-induced bowel dysfunction (OBD).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00597428
Study type	Interventional
Source	Mallinckrodt
Contact
Status	Completed
Phase	Phase 3
Start date	August 2007
Completion date	March 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06334198` - The Effect of Naldemedine on Opioid-induced Bowel Dysfunction	Phase 2
Completed	`NCT01298219` - Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)	Phase 3
Completed	`NCT00620061` - Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone	Phase 3
Completed	`NCT00595946` - Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone	Phase 3
Completed	`NCT06385561` - The Influence of Tramadol on Opioid-induced Bowel Dysfunction	Phase 2
Recruiting	`NCT04876508` - The Efficacy of Acupressure in Managing Opioid-induced Constipation	N/A